日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

Ivosidenib治疗IDH1突变晚期胆管癌患者的最终总生存期疗效结果:3期随机临床试验ClarIDHy

Zhu, Andrew X; Macarulla, Teresa; Javle, Milind M; Kelley, R Kate; Lubner, Sam J; Adeva, Jorge; Cleary, James M; Catenacci, Daniel V T; Borad, Mitesh J; Bridgewater, John A; Harris, William P; Murphy, Adrian G; Oh, Do-Youn; Whisenant, Jonathan R; Lowery, Maeve A; Goyal, Lipika; Shroff, Rachna T; El-Khoueiry, Anthony B; Chamberlain, Christina X; Aguado-Fraile, Elia; Choe, Sung; Wu, Bin; Liu, Hua; Gliser, Camelia; Pandya, Shuchi S; Valle, Juan W; Abou-Alfa, Ghassan K

A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC

一项针对肝细胞癌患者的真实世界观察性队列研究:TARGET-HCC 研究的设计和原理

Cabrera, Roniel; Singal, Amit G; Colombo, Massimo; Kelley, R Kate; Lee, Hannah; Mospan, Andrea R; Meyer, Tim; Newell, Pippa; Parikh, Neehar D; Sangro, Bruno; Reddy, K Rajender; Watkins, Stephanie; Zink, Richard C; Di Bisceglie, Adrian M

Key challenges for drugs in clinical development for cholangiocarcinoma

胆管癌药物临床开发面临的主要挑战

Keenan, Bridget P; Kelley, R Kate Katie

Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women

孕妇和产后妇女皮下注射丁丙诺啡缓释剂

Cleary, Erin M; Byron, R Kate; Hinely, Katherine A; Talley, Allison W; Costantine, Maged M; Rood, Kara M

A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS

单个H/ACA小核仁RNA介导致癌RAS下游的肿瘤抑制

Mary McMahon #, Adrian Contreras #, Mikael Holm, Tamayo Uechi, Craig M Forester, Xiaming Pang, Cody Jackson, Meredith E Calvert, Bin Chen, David A Quigley, John M Luk, R Kate Kelley, John D Gordan, Ryan M Gill, Scott C Blanchard, Davide Ruggero

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

一项针对肝细胞癌伴边缘肝储备的肝移植候选者的前瞻性II期临床试验,研究药物洗脱微球化疗栓塞术的疗效。

Fidelman, Nicholas; Johanson, Curt; Kohi, Maureen P; Kolli, K Pallav; Kohlbrenner, Ryan M; Lehrman, Evan D; Taylor, Andrew G; Kelley, R Kate; Yao, Francis Y; Roberts, John P; Kerlan, Robert K

Role of personality in tobacco smoking behavior in corporate sector: A cross-sectional study

人格因素在企业员工吸烟行为中的作用:一项横断面研究

Kulkarni, Prathamesh S; Parkar, Shubhangi R; Kate, Natasha; Ninawe, Kaneenica; Limbachiya, Rimple

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

NCCN指南解读:肝胆肿瘤,2017年第1版

Benson, Al B 3rd; D'Angelica, Michael I; Abbott, Daniel E; Abrams, Thomas A; Alberts, Steven R; Saenz, Daniel Anaya; Are, Chandrakanth; Brown, Daniel B; Chang, Daniel T; Covey, Anne M; Hawkins, William; Iyer, Renuka; Jacob, Rojymon; Karachristos, Andrea; Kelley, R Kate; Kim, Robin; Palta, Manisha; Park, James O; Sahai, Vaibhav; Schefter, Tracey; Schmidt, Carl; Sicklick, Jason K; Singh, Gagandeep; Sohal, Davendra; Stein, Stacey; Tian, G Gary; Vauthey, Jean-Nicolas; Venook, Alan P; Zhu, Andrew X; Hoffmann, Karin G; Darlow, Susan

Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative

支付方对遗传性癌症检测的覆盖范围:障碍、机遇及其对精准医疗计划的影响

Trosman, Julia R; Weldon, Christine B; Douglas, Michael P; Kurian, Allison W; Kelley, R Kate; Deverka, Patricia A; Phillips, Kathryn A

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

一项多中心、开放标签的II期临床试验,研究MEK联合EGFR抑制剂治疗化疗难治性晚期胰腺腺癌的疗效

Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica; Mirzoeva, Olga M; Joseph, Nancy M; Talasaz, AmirAli; Kuhn, Peter; Tempero, Margaret A; Collisson, Eric A; Kelley, R Kate; Venook, Alan P; Dito, Elizabeth; Ong, Anna; Ziyeh, Sharvina; Courtin, Ryan; Linetskaya, Regina; Tahiri, Sanaa; Korn, W Michael